Turkey
Key Insights
- 1
No psychedelic therapies are approved for routine patient use in Turkey; ketamine and esketamine appear confined to hospital-based medical practice, not decriminalised access.
- 2
Turkey's database shows 9 trials, 0 active, and 2 research organisations; ketamine and esketamine account for all tracked compounds.
- 3
A 2025 Turkish randomised trial found ketamine affected mood after day-case surgery, giving the country a rare domestic clinical signal beyond depression studies.
- 4
Momentum is thin but real: the research base is concentrated in just 2 organisations, suggesting one or two centres could quickly move the field if regulation or funding shifts.
Reimbursed Care Access
Turkey maintains a restrictive national control regime for classical serotonergic and empathogenic psychedelics: most tryptamines, phenethylamines and classic psychedelic plants/ preparations are scheduled and not available outside authorised research or prosecution exceptions. Medical use of ketamine as an anaesthetic and analgesic is well established in Turkish clinical practice; esketamine (marketed as SPRAVATO in some markets) appears in Turkish product information sources but is not known to be broadly reimbursed by the public social security system (SGK) and is administered under specialist supervision. Other compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are effectively prohibited for general medical use and only accessible in authorised clinical trials or not at all.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Turkey.